The “Great Debate” at Immunotherapy Bridge 2022, Naples, November 30th–December 1st, 2022
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
The “Great Debate” at Immunotherapy Bridge 2022, Naples, November 30th–December 1st, 2022 ; volume:21 ; number:1 ; day:22 ; month:4 ; year:2023 ; pages:1-10 ; date:12.2023
Journal of translational medicine ; 21, Heft 1 (22.4.2023), 1-10, 12.2023
- Urheber
-
Ascierto, Paolo A.
Brentjens, Renier
Khleif, Samir N.
Odunsi, Kunle
Rezvani, Katayoun
Ruella, Marco
Sullivan, Ryan J.
Fox, Bernard A.
Puzanov, Igor
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12967-023-04117-3
- URN
-
urn:nbn:de:101:1-2023090209090406139725
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ascierto, Paolo A.
- Brentjens, Renier
- Khleif, Samir N.
- Odunsi, Kunle
- Rezvani, Katayoun
- Ruella, Marco
- Sullivan, Ryan J.
- Fox, Bernard A.
- Puzanov, Igor
- SpringerLink (Online service)
Ähnliche Objekte (12)
The “Great Debate” at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022
Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th–December 1st, 2022)
Melanoma: the role of surgery in the era of new therapies
What have we learned from cancer immunotherapy in the last 3 years?
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Combination therapy: the next opportunity and challenge of medicine
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st–3rd, 2022—Naples, Italy)
Melanoma: A model for testing new agents in combination therapies
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
World-Wide Immunoscore Task Force: meeting report from the “Melanoma Bridge”, Napoli, November 30th–December 3rd, 2016
The “Great Debate” at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022
Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th–December 1st, 2022)
Melanoma: the role of surgery in the era of new therapies
What have we learned from cancer immunotherapy in the last 3 years?
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Combination therapy: the next opportunity and challenge of medicine
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st–3rd, 2022—Naples, Italy)
Melanoma: A model for testing new agents in combination therapies
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
World-Wide Immunoscore Task Force: meeting report from the “Melanoma Bridge”, Napoli, November 30th–December 3rd, 2016
The “Great Debate” at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022
Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th–December 1st, 2022)
Melanoma: the role of surgery in the era of new therapies
What have we learned from cancer immunotherapy in the last 3 years?
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Combination therapy: the next opportunity and challenge of medicine
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st–3rd, 2022—Naples, Italy)
Melanoma: A model for testing new agents in combination therapies
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application